Compositions comprising ketamine, optionally in combination with n-acylethanolamines, and uses thereof
AssigneeClearmind Labs Corp.
InventorAdi ZULOFF-SHANI
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to pharmaceutical compositions comprising ketamine, or a salt thereof, and combinations of ketamine, or a pharmaceutically acceptable salt thereof and an N-acylethanolamine, or a salt thereof, and at least one pharmaceutically acceptable carrier and/or excipient, and their use in methods of treating depression, suicidal ideation, bipolar disorder, seizures, and pain by administrating said compositions to a subject in need thereof in a therapeutically effective amount.
Claims42
A pharmaceutical composition comprising ketamine, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier and/or excipient.
A method of treating depression or suicidal ideation, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising ketamine, or a pharmaceutically acceptable salt thereof.
A method of treating pain, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising ketamine, or a pharmaceutically acceptable salt thereof.
A method of treating seizures, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising ketamine, or a pharmaceutically acceptable salt thereof.
A method of treating bipolar disorder, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising ketamine, or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising ketamine or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier and/or excipient.
A method of treating depression, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising ketamine, or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine, or a pharmaceutically acceptable salt thereof.
A method of treating suicidal ideation, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising ketamine, or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine, or a pharmaceutically acceptable salt thereof.
A method of treating seizures, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising ketamine, or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine, or a pharmaceutically acceptable salt thereof.
A method of treating bipolar disorder, comprising administrating to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising ketamine, or a pharmaceutically acceptable salt thereof, and an N-acylethanolamine, or a pharmaceutically acceptable salt thereof.
The pharmaceutical composition of any preceding claim, wherein the N-acylethanolamine is selected from the group consisting of N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), salts thereof and any combination thereof.
The method of any preceding claim, wherein the N-acylethanolamine is selected from the group consisting of N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), salts thereof and any combination thereof.
The pharmaceutical composition of any preceding claim, wherein the N-acylethanolamine is PEA or a pharmaceutically acceptable salt thereof.
The method of any preceding claim, wherein the N-acylethanolamine is PEA or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.